Anesthesia Management in Endovascular Therapy for Ischemic Stroke (AMETIS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03229148|
Recruitment Status : Recruiting
First Posted : July 25, 2017
Last Update Posted : September 5, 2017
|Condition or disease||Intervention/treatment||Phase|
|Stroke Thrombectomy Anesthesia Conscious Sedation||Procedure: General anaesthesia Procedure: Conscious Sedation||Not Applicable|
Since 2015, the management of anterior acute ischemic stroke (AIS) involves endovascular treatment with mechanical thrombectomy (MT). This urgent, difficult and uncomfortable procedure in frail patients requires multidisciplinary care ideally involving neurologists, interventional neuroradiologists and anesthesiologists.
Two anesthetic strategies are currently used: pharmacologic sedation in spontaneous ventilation or general anesthesia with tracheal intubation. General anesthesia provides strict immobility, protects the airway and avoids emergency intubation in case of severe procedural complication (notably vomiting and aspiration). Sedation is a frequently used alternative because of (1) a rapid execution which could reduce delay to reperfusion, (2) a lower risk of blood pressure drop that may compromise cerebral blood flow in the penumbra area, (3) the theoretical capacity to assess neurological status during the procedure and (4) the supposed risk of complications associated with mechanical ventilation and intravenous anesthestics on brain metabolism. Nevertheless, sedation exposes to dramatic complications in case of patient agitation and movements.
The choice of the ideal anesthesic management is still lacking. Old retrospective studies seemed to favor sedation with worst neurological outcome associated with general anesthesia. Nevertheless, these datas suffered methodological issues with selection bias: more severe patients based on NIHSS score were rather treated with general anesthesia and blood pressure was not controlled. Recent studies that demonstrated the benefit of MT did not include a specific anesthetic protocol and none of the studies currently available included a blood pressure management protocol that appears to be an essential component of cerebral perfusion. A subgroup analysis of the MR Clean study, including patients with an identical initial NIHSS score, did not find benefit from MT in patients with general anesthesia compared to those receiving sedation. Finally, authors concluded that performing a MT under general anesthesia would significantly lengthen the reperfusion delay and nullify the benefit of MT.
The prospective, randomized, single-center SIESTA trial, conducted in 150 patients with an anterior circulation AIS, found no difference in the early neurological improvement (primary endpoint), assessed on the change in NIHSS score between admission and the 24th hour, between the conscious sedation group and the general anesthesia group. There were a tendency for a better 3-month neurological outcome in the general anesthesia group (37% vs 18% of patients with a Modified Rankin score of 0-2 in the general anesthesia and conscious sedation groups respectively), but it was not possible to conclude due to a lack of statistical power.
Due to the increasing number of patients eligible for endovascular MT and the potential implication of these two anesthetic management on the functional outcome, a study comparing general anesthesia and sedation during a MT seems essential as specified in the recent updated American Stroke Association guidelines.
The objective of this study is to assess whether sedation or general anesthesia during endovascular treatment with mechanical thrombectomy is associated with a difference in morbidity (neurological outcome and peri-procedural complications), in anterior circulation AIS.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||270 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Multicentic, prospective, open, in parallel groups, stratified and randomised study.|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||It is an open label trial because it is not possible to maintain the anesthesiologist and patient blinded during the procedure. However, all subsequent evaluations will be conducted by clinical research staff blinded to the randomization group.|
|Official Title:||Anesthesia Management in Endovascular Therapy for Ischemic Stroke: A Multicenter Randomised Study|
|Actual Study Start Date :||August 31, 2017|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||January 2020|
Active Comparator: General anaesthesia
In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
Procedure: General anaesthesia
Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
Active Comparator: Conscious Sedation
In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
Procedure: Conscious Sedation
A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
- patients with an altered neurological outcome at day 90 or a serious complication within 7 days post-procedure [ Time Frame: on day 7 and day 90 ]A composite judgment criterion evaluating the proportion of patients with an altered neurological outcome (Modified Rankin scale > 2) at day 90 and / or a serious complication within 7 days post-procedure among: Procedural radiological complication: perforation or arterial dissection, Pulmonary complication: infectious broncho-pneumonia, Cardiovascular complication: myocardial infarction, acute heart failure, Neurological complication: "malignant" transformation of stroke
- Modified Rankin Scale [ Time Frame: at day 90 ]
- NIHSS score [ Time Frame: at 24 hours of the procedure and at day 7 ]
- Maximum difference in systolic blood pressure (SBP) during the procedure [ Time Frame: at day 90 ]as defined by the difference between the maximum SBP before procedure and the minimum SBP during the procedure
- Area under the mean arterial pressure curve [ Time Frame: at day 90 ]
- Area under the curve of pulsed oxygen saturation [ Time Frame: at day 90 ]
- Arterial perforation per procedure [ Time Frame: at day 90 ]
- Arterial dissection per procedure [ Time Frame: at day 90 ]
- "Stroke / arterial puncture " delay in minutes [ Time Frame: at day 1 ]
- "Stroke / reperfusion " delay in minutes [ Time Frame: at day 1 ]
- TICI recanalization score [ Time Frame: at day 1 ]
- Myocardial infarction [ Time Frame: at day 7 ]
- Infectious Broncho-Pneumonia [ Time Frame: at day 7 ]
- Acute cardiac failure with pulmonary edema [ Time Frame: at day 7 ]
- "Malignant" transformation of stroke [ Time Frame: at day 7 ]defined by the occurrence of a mass effect related to a large cerebral infarction requiring medical and / or surgical treatment (craniectomy)
- Symptomatic cerebral haemorrhage [ Time Frame: at day 7 ]defined by the occurrence of neurological deterioration in relation to intracranial or meningeal haemorrhage
- Hospital length of stay [ Time Frame: at day 1 ]
- stroke center length of stay [ Time Frame: at day 1 ]
- Hospitalization in intensive care unit [ Time Frame: at day 7 ]
- Mortality [ Time Frame: on day 7 and day 90 ]
- Procedural Feasibility score estimated by the radiologist [ Time Frame: at day 7 ]
- Feasibility score estimated by the anesthesiologist [ Time Frame: at day 7 ]
- Acceptability score estimated by the patient [ Time Frame: at day 7 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03229148
|Contact: Patrick LACARIN||04 73 75 11 email@example.com|
|CHU de Clermont-Ferrand||Recruiting|
|Clermont-Ferrand, Auvergne, France, 63003|
|Contact: Patrick LACARIN 04 73 75 11 95 firstname.lastname@example.org|
|Principal Investigator: Charlotte FERNANDEZ-CANAL, MD|
|Principal Investigator: Russel CHABANNE, MD|
|Sub-Investigator: Anne-Claire LUKASZEWICZ, MD PhD|
|Sub-Investigator: Serge MOLLIEX, MD PhD|
|Sub-Investigator: Thomas GEERAERTS, MD PhD|
|Sub-Investigator: Pierre-François PERRIGAULT, MD|
|Sub-Investigator: Lionel VELLY, MD PhD|
|Sub-Investigator: Benoit TAVERNIER, MD PhD|
|Sub-Investigator: Marie GILLES-BARAY, MD|
|Sub-Investigator: Vincent DEGOS, MD PhD|
|Principal Investigator:||Charlotte Fernandez-Canal, MD||CHU de Clermont-Ferrand|
|Principal Investigator:||Russel Chabanne, MD||CHU de Clermont-Ferrand|